VEGFD
Vascular endothelial growth factor D
Also known as: FIGF, VEGF-D, VEGFD_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O43915
- Gene
- VEGFD
- Ensembl
- ENSG00000165197
- Chromosome
- X
- Canonical length
- 354 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C. Read-through transcription has been observed between this locus and the upstream PIR (GeneID 8544) locus. [provided by RefSeq, Feb 2011]
Canonical amino-acid sequenceUniProt
354 residues, UniProt reviewed canonical sequence.
>O43915|VEGFD
1 MYREWVVVNV FMMLYVQLVQ GSSNEHGPVK RSSQSTLERS EQQIRAASSL EELLRITHSE
61 DWKLWRCRLR LKSFTSMDSR SASHRSTRFA ATFYDIETLK VIDEEWQRTQ CSPRETCVEV
121 ASELGKSTNT FFKPPCVNVF RCGGCCNEES LICMNTSTSY ISKQLFEISV PLTSVPELVP
181 VKVANHTGCK CLPTAPRHPY SIIRRSIQIP EEDRCSHSKK LCPIDMLWDS NKCKCVLQEE
241 NPLAGTEDHS HLQEPALCGP HMMFDEDRCE CVCKTPCPKD LIQHPKNCSC FECKESLETC
301 CQKHKLFHPD TCSCEDRCPF HTRPCASGKT ACAKHCRFPK EKRAAQGPHS RKNPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against VEGFD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 40 nTPM
Expression across tissuesHPA
Tissue
- lung: 40 nTPM
- tongue: 22 nTPM
- breast: 19 nTPM
- skeletal muscle: 17 nTPM
- heart muscle: 15 nTPM
- adipose tissue: 11 nTPM
Single-cell type
- myonuclei: 103 nCPM
- fibroblasts: 67 nCPM
- fibro-adipogenic progenitors: 28 nCPM
- other brain neurons: 22 nCPM
- retinal ganglion cells: 19 nCPM
- brain inhibitory neurons: 17 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 3 nTPM
- pons: 2.9 nTPM
- cerebral cortex: 2.8 nTPM
- white matter: 2.7 nTPM
- basal ganglia: 2.4 nTPM
- thalamus: 2.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.15
- gnomAD pLI
- 0
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- dopaminergic neuron differentiation
- fibroblast proliferation
- induction of positive chemotaxis
- positive regulation of cell division
- positive regulation of cell population proliferation
- positive regulation of mast cell chemotaxis
- response to bacterium
- response to hypoxia
- sprouting angiogenesis
- vascular endothelial growth factor receptor signaling pathway
- vascular endothelial growth factor signaling pathway
Molecular functions
- chemoattractant activity
- growth factor activity
- identical protein binding
- platelet-derived growth factor receptor binding
- vascular endothelial growth factor receptor 3 binding
- vascular endothelial growth factor receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of VEGFD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VEGFD as an antibody target. Whether an autoantibody or antibody against VEGFD could matter depends on whether native VEGFD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VEGFD is annotated as secreted, so native VEGFD circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label VEGFD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...